MoonLake Immunotherapeutics
$17.89
▲
5.08%
2026-04-21 08:11:01
www.moonlaketx.com
NCM: MLTX
Explore MoonLake Immunotherapeutics stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.32 B
Current Price
$17.89
52W High / Low
$62.75 / $5.95
Stock P/E
—
Book Value
$4.27
Dividend Yield
—
ROCE
-64.61%
ROE
-60.78%
Face Value
—
EPS
$-3.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
130
Beta
1.19
Debt / Equity
24.86
Current Ratio
9.27
Quick Ratio
9.27
Forward P/E
-4.96
Price / Sales
—
Enterprise Value
$969.97 M
EV / EBITDA
-4
EV / Revenue
—
Rating
Buy
Target Price
$26.71
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 2. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 3. | Pyxis Oncology, Inc. | $1.7 | — | $104.3 M | — | -119.93% | -91.44% | $5.55 / $0.89 | $0.85 |
| 4. | Edgewise Therapeutics, Inc. | $33.97 | — | $3.69 B | — | -36.44% | -34.19% | $35 / $12.15 | $4.92 |
| 5. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 6. | Kiora Pharmaceuticals, Inc. | $2.52 | — | $9.96 M | — | -45.87% | -51.74% | $4.18 / $1.76 | $4.29 |
| 7. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -65.22 M | -71.43 M | -60.7 M | -47.48 M | -49.58 M | — |
| Net Profit | -62.43 M | -69.73 M | -55.22 M | -39.94 M | -45.6 M | — |
| EPS in Rs | -0.87 | -0.97 | -0.77 | -0.56 | -0.64 | -0.56 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -244.83 M | -143.09 M | -54.12 M | -65.06 M |
| Net Profit | -227.32 M | -118.94 M | -36.01 M | -49.97 M |
| EPS in Rs | -3.17 | -1.66 | -0.5 | -0.7 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 424.43 M | 477.93 M | 526.54 M | 76.84 M |
| Total Liabilities | 119.95 M | 24.54 M | 13.05 M | 8.08 M |
| Equity | 304.48 M | 446.82 M | 495.68 M | 48.9 M |
| Current Assets | 421.69 M | 474.29 M | 514.17 M | 76.51 M |
| Current Liabilities | 45.48 M | 22.46 M | 9.97 M | 7.67 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -196.01 M | -116.59 M | -42.78 M | -55.89 M |
| Investing CF | 202.99 M | -205.6 M | -25.18 M | -32.34 M |
| Financing CF | 146 M | 51.31 M | 479.7 M | 119.69 M |
| Free CF | -196.04 M | -117.11 M | -43.06 M | -55.91 M |
| Capex | -0.04 M | -0.52 M | -0.28 M | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -91.13% | -230.31% | 27.95% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.